The group's principal activity is to develop proprietary therapeutics for the treatment of central nervous system (cns) disorders, cancer and cardiovascular disease. The product development programs of the group focus on large pharmaceutical markets with significant unmet medical needs and commercial potential. The group develops products independently and also in collaboration with companies like novartis pharma ag and schering ag and government sponsored clinical cooperative groups. The trademarks of the group are spheramine (R), pivanex (R), probuphine (R), ceavac (R), triab(R) , trigem(TM) and ccm tm. In Oct 2003, the group acquired developmental therapeutics inc.
